Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

OM - Outset Medical, Inc. Latest News | Finranks

Home

OM

(OM)

NMS – Real Time Price. Currency in USD

3.56

+0.04 (1.14%)

At close: Mar 27, 2026, 4:00 PM EDT

3.60

+0.04 (1.12%)

After-hours: Mar 27, 2026, 7:26 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results

Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results

SAN JOSE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the fourth quarter and year ended December 31, 2025.

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned

SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) of its next-generation Tablo platform, designed to deliver enterprise-level security, reliability and connectivity for hospitals, health systems and home providers of dialysis.

Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.